Highlights

  • Resonance Health has reported a full year of improved financial performance across its business.
  • The company returned to full-year profitability alongside gains in cash generation.
  • Growth was recorded across its clinical trial services, clinic network and diagnostics technology segments.
  • Management has issued an outlook for the year ahead based on conservative assumptions.

Resonance Health Ltd (ASX:RHT) has reported an improved set of financial results for the year ended 30 June 2026, highlighting a broader shift in the company's underlying performance across its diagnostic technology and clinical trial services businesses. The results mark a return to full-year profitability for the healthcare technology group, alongside gains in cash generation across its main operating segments. For readers tracking the ASX healthcare sector, Resonance Health's latest year offers an example of how a diversified diagnostics and clinical services Business can build momentum across multiple Revenue streams simultaneously.

Resonance Health operates at the intersection of medical imaging, software-based diagnostic tools and outsourced clinical trial services, a combination that allows the company to support pharmaceutical clients while also building a physical clinic network and a technology-driven diagnostics pipeline. The FY26 results provide an opportunity to consider how each of these strands contributed to the year's overall improvement, and what management has signalled about sustaining that improvement into the year ahead.

A Return to Full-Year Profitability

Resonance Health achieved growth across its financial year ending 30 June 2026, with the company returning to full-year profitability on a net profit after tax basis and reporting a notable increase in full-year revenue. Alongside the top-line improvement, operating performance also improved meaningfully, with the company generating positive operating cashflow in every quarter of the year and boosting free cashflow by a considerable Margin compared with the prior period.

Underlying earnings, measured on a normalised EBITDA basis, grew at what the company describes as a healthy operating margin, indicating that the improvement in revenue was accompanied by an improvement in the efficiency of converting that revenue into underlying profit. The company also ended the year in an improved cash position, moving to a position of net cash, an improvement on where it stood at the end of the prior financial year. Positive operating cashflow being sustained across all four quarters is also notable in itself, since it points to a level of consistency in cash generation across the year rather than a result concentrated in a single reporting period.

Segment Performance Across the Business

Growth across the year was driven in part by Resonance Clinical, which recorded a notable revenue increase driven primarily by service agreements with major pharmaceutical clients supporting clinical trial work. This segment's growth reflects the ongoing role that Resonance Health plays in supporting pharmaceutical development programs through specialised imaging and diagnostic services used in trial settings.

The TrialsWest clinic network also expanded during the period, with the established Osborne Park Facility remaining consistently profitable and the newer Mandurah clinic approaching a breakeven position in its first year of operation. Meanwhile, the Software-as-a-Medical-Device segment maintained its momentum, supported by a growing forward order and tendered pipeline, including continued development work on its non-invasive liver fibrosis assessment technology, an area the company continues to position as a longer-term growth opportunity. Taken together, the three segments illustrate a business model that blends established, cash-generative operations with newer clinic sites and an emerging diagnostics technology pipeline still working toward broader commercial adoption.

Outlook for the Year Ahead

Looking to the 2027 financial year, management has provided guidance ranges for both revenue and normalised EBITDA, built on what the company describes as conservative assumptions that do not Factor in any new acquisitions or geographic expansion. This approach suggests that the guidance reflects an extension of existing operations and contracts rather than assuming additional growth initiatives that have not yet been confirmed.

Taken together, the improved cash position, the return to full-year profitability and the guidance provided for the coming year point to a business that management believes has built a more sustainable operating base across its diagnostics, clinical trial services and clinic network segments. Whether this trajectory continues will depend on factors including client Demand for clinical trial services, further progress in the SaMD pipeline and the ongoing performance of the clinic network. The decision to base guidance on conservative assumptions, rather than assuming additional acquisitions or new markets, may also give readers a clearer baseline against which to judge the company's actual performance as the new financial year unfolds.

Key Insights

Resonance Health's results for the year ended 30 June 2026 illustrate a period of improved financial and operating performance across its diagnostics, clinical trial services and clinic businesses. The combination of a return to profitability, improved cashflow generation and an improved cash position suggests the underlying business gained traction across each of its three main segments during the year. At the same time, the guidance provided for FY27 is described by management as conservative, built on existing operations rather than new acquisitions, which may be a relevant consideration for readers assessing the sustainability of the improvement seen during FY26. As with any single-year result, ongoing performance across Resonance Clinical, TrialsWest and the SaMD segment will be worth monitoring in subsequent reporting periods, particularly how the Mandurah clinic progresses toward full profitability and how the liver fibrosis assessment technology advances through its development and tendering pipeline over the coming year.